Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jan;25(1):101-6.
doi: 10.1007/s13337-013-0166-8. Epub 2013 Sep 27.

A reporter based single step assay for evaluation of inhibitors targeting HIV-1 Rev-RRE interaction

Affiliations

A reporter based single step assay for evaluation of inhibitors targeting HIV-1 Rev-RRE interaction

Sumeer Raina et al. Virusdisease. 2014 Jan.

Abstract

Human immunodeficiency virus regulatory protein Rev (regulator of viral expression) is translated from a monocistronic transcript produced early in the viral replication cycle. Rev binds to the cis-acting, highly structured viral RNA sequence Rev response element (RRE) and the Rev-RRE complex primarily controls nucleocytoplasmic transport of viral RNAs. Inhibition of Rev-RRE interaction therefore is an attractive target to block viral transport. We have developed a stable cell line carrying a lentiviral vector harboring a rev gene and a co-linear Rev-dependent GFP/luciferase reporter gene cassette and thus constitutively expressing the reporter proteins. Dose-dependent luciferase activity inhibition in the indicator cell line by known small molecule inhibitors Proflavin and K37 established the specificity of the assay. This novel single step assay, that involves use of very small amount of reagents/cells and addition of test material as the only manipulation, can therefore be useful for screening therapeutically potential Rev-RRE interaction inhibitors.

Keywords: K-37; Lentiviral vector; Luciferase assay; Proflavin; Rev–RRE interaction; Single-step assay.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Genomic configuration of the Rev-dependent reporter and trans-activator Rev cassettes in the plasmids. a pGLG-RRE, b pEFIα-Rev and reporter-activator and reporter in lentiviral transfer vector. c pLV-GLG-RRE-Rev, d pLV-GLGRRE, respectively
Fig. 2
Fig. 2
Inhibition of Rev-mediated luciferase reporter trans-activation under different doses of a Proflavin and b K-37 AZT served as a negative control. Columns and error bars are mean ± SD (n = 3)
Fig. 3
Fig. 3
Effect of drugs on indicator cell viability and Rev expression. a Cell viability at indicated doses of K37, Proflavin and AZT by MTT assay; Rev protein expression in presence of b Proflavin and c K-37. Densitometric analysis of Rev expression levels represented as fold changes, respectively, and beta-actin served as loading control. Columns and error bars are mean ± SD (n = 3)

References

    1. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T, Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol. 1998;53:1097–1103. - PubMed
    1. Berthold E, Maldarelli F. Cis-acting elements in human immunodeficiency virus type 1 RNAs direct viral transcripts to distinct intranuclear locations. J Virol. 1996;70:4667–4682. - PMC - PubMed
    1. Brandt S, Blissenbach M, Grewe B, Konietzny R, Grunwald T, Uberla K. Rev proteins of human and simian immunodeficiency virus enhance RNA encapsidation. PLoS Pathog. 2007;3:e54. doi: 10.1371/journal.ppat.0030054. - DOI - PMC - PubMed
    1. Chande AG, Baba M, Mukhopadhyaya R. A single step assay for rapid evaluation of inhibitors targeting HIV type 1 Tat-mediated long terminal repeat transactivation. AIDS Res Hum Retrovir. 2012;28:902–906. doi: 10.1089/aid.2011.0228. - DOI - PubMed
    1. Chande AG, Raina S, Dhamne H, Kamat RH, Mukhopadhyaya R. Multiple platforms of a HIV-2 derived lentiviral vector for expanded utility. Plasmid. 2013;69:90–95. doi: 10.1016/j.plasmid.2012.09.006. - DOI - PubMed